NASDAQ: LUNG February 2025 © 2025 Pulmonx Corporation 1 Forward Looking Statement This presentation and certain statements made during this presentation contain forward-looking statements that involve risks and uncertainties. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business ...

Pulmonx (LUNG) FY Conference June 11, 2025 10:00 AM ET Speaker0 Good morning, everyone. My name is Steve Williamson. I'm the President and CEO of Palmonix. Thanks for joining us today. I'll get started with a forward looking statement. If you're looking for more information on this and more detailed information, it can be found on the Investor section of our website under Investor Relations or our full 10 ks. Investment highlights. So here's pulmonics. This is what I'd like you to remember about pulmonics. ...

Breakthrough Second-Line Treatment Demonstrated Survival Advantage over Standard-of-Care Chemotherapy Late-Breaking Data Presented at ASCO 2025 and Simultaneously Published in The New England Journal of MedicineTHOUSAND OAKS, Calif., June 2, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new interim results from the global Phase 3 DeLLphi-304 trial showing IMDELLTRA® (tarlatamab-dlle) reduced the risk of death by 40% and significantly extended median overall survival (OS) by more than five months ...

REDWOOD CITY, Calif., May 28, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today announced the company will be presenting at the Goldman Sachs 46th Annual Global Health Care Conference in Miami on Wednesday, June 11, 2025, at 7:00 AM PT / 10:00 AM ET. A live and archived webcast of the presentation will be available on “Investors” section of the Pulmonx website at https://investors.pulmonx.com/. A ...

Pulmonx (LUNG) 2025 Conference May 14, 2025 12:35 PM ET Speaker0 Thanks for coming out today. I appreciate it. We've got some forward looking statements we'll be making. The information that you need, you can find in our SEC documents, but I wanted to call that out. Before you start, right now, are five hundred thousand patients in The United States that are suffocating, literally suffocating. Outside The United States, Seven Hundred Thousand patients that are suffocating. They can't get enough oxygen so th ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39562 PULMONX CORPORATION (Exact name of registrant as specified in its charter) Delaware 77-0424412 (State or other jur ...

Pulmonx (LUNG) Q1 2025 Earnings Call April 30, 2025 04:30 PM ET Company Participants Laine Morgan - Associate Vice PresidentSteve Williamson - President & CEOMehul Joshi - Chief Financial OfficerAnnie Ponsi - Intern Sophomore ExplorersJohn Young - Director - Healthcare Equity ResearchJane-Marie Lai - Equity Research Senior Associate Conference Call Participants Frank Takkinen - Senior Research AnalystJason Bednar - Senior Research Analyst Operator Ladies and gentlemen, thank you for standing by and welcome ...

Pulmonx (LUNG) Q1 2025 Earnings Call April 30, 2025 04:30 PM ET Speaker0 Ladies and gentlemen, thank you for standing by and welcome to PalmaNick's First Quarter twenty twenty five Earnings Conference Call. At this time, all participants are in a listen only mode. After the speakers' presentation, there will be a question and answer Please be advised that today's conference is being recorded. I would now like to turn the conference over to Lane Morgan, Investor Relations. Please go ahead. Speaker1 Good afte ...

REDWOOD CITY, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the first quarter of 2025 ended March 31, 2025. Recent Highlights Achieved worldwide revenue of $22.5 million in the first quarter of 2025, a 20% increase over the same period last year and an increase of 21% on a constant currency basisDelivered $8.3 million in international revenue i ...

REDWOOD CITY, Calif., April 16, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the first quarter of 2025 after the close of trading on Wednesday, April 30, 2025. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET. A live and archived webcast of the event will be available on the “Investors” se ...